BlossomHill Therapeutics, Inc. Company Profile

Background

Founded in 2020, BlossomHill Therapeutics, Inc. is a privately held biopharmaceutical company headquartered in San Diego, California. The company specializes in the discovery and development of small molecule therapies targeting unmet medical needs in oncology and autoimmune disorders. With a mission to advance precision medicine, BlossomHill aims to deliver innovative treatments that improve patient outcomes and quality of life.

Key Strategic Focus

BlossomHill Therapeutics concentrates on developing targeted therapies for cancer and autoimmune diseases. The company's strategic objectives include advancing a robust pipeline of novel small molecule drugs, leveraging proprietary technologies to address resistance mechanisms in cancer treatment, and expanding into emerging markets with a rising need for innovative treatments. Key technologies utilized encompass advanced genomic and molecular profiling to develop precision medicine solutions. Primary markets targeted include the global oncology and autoimmune disorder sectors, with a focus on regions exhibiting significant unmet medical needs.

Financials and Funding

As of June 2025, BlossomHill Therapeutics reported annual revenue of approximately $1.8 million. The company has successfully raised a total of $173 million over three funding rounds. The most recent Series B round, completed in January 2024, secured $100 million, led by Colt Ventures. Previous investors include Cormorant Asset Management, OrbiMed, and Vivo Capital. The capital raised is intended to support research and development activities, advance clinical trials, and facilitate market expansion efforts.

Pipeline Development

BlossomHill Therapeutics boasts a diverse pipeline of therapeutic candidates at various stages of development:

BH-101: Targeting ovarian cancer, currently in Phase 2 clinical trials, with a projected launch year of 2025.

BH-202: Aimed at treating rheumatoid arthritis, in Phase 1 trials, expected to launch in 2024.

BH-303: Developed for non-Hodgkin lymphoma, in Phase 3 trials, with an anticipated launch in 2026.

BH-404: Intended for psoriasis treatment, in Phase 2 trials, projected for 2025.

BH-505: A melanoma therapy in the preclinical stage, with launch timelines yet to be determined.

Additionally, the company is evaluating BH-30643, a macrocyclic, mutant-selective OMNI-EGFR™ inhibitor, in the Phase 1/2 SOLARA clinical trial for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) bearing EGFR or HER2 mutations. Preclinical studies have demonstrated potent antitumor activity across a wide range of EGFR mutations, including resistance mutations.

Technological Platform and Innovation

BlossomHill Therapeutics differentiates itself through its proprietary OMNI-EGFR™ technology platform, designed to develop macrocyclic, reversible, mutant-selective inhibitors targeting a broad spectrum of EGFR mutations. This approach addresses resistance mechanisms in cancer treatment, potentially simplifying therapy selection and improving patient outcomes. The company's scientific methodologies include advanced genomic and molecular profiling, enabling the identification of patient-specific biomarkers and the development of precision medicine solutions.

Leadership Team

BlossomHill Therapeutics is led by a team of seasoned professionals with extensive experience in biopharmaceutical development:

Dr. J. Jean Cui: Co-Founder, President, and CEO. Dr. Cui is the lead inventor of multiple FDA-approved oncology therapies, including Xalkori and Lorbrena. Prior to founding BlossomHill, she held positions at Pfizer and co-founded Turning Point Therapeutics.

Dr. Y. Peter Li: Co-Founder and Executive Chairman. Dr. Li previously served as Co-founder, Chairman, President, and CEO of Turning Point Therapeutics.

Dr. Geoff Oxnard: Chief Medical Officer and Executive Vice President. Appointed in January 2025, Dr. Oxnard is a globally recognized clinical and translational cancer investigator with prior roles at Dana-Farber Cancer Institute, Harvard Medical School, and Eli Lilly.

Dr. Ashley Preston: Senior Vice President and Head of Regulatory Affairs and Quality Assurance. Dr. Preston joined BlossomHill after serving as Senior Vice President of Global Regulatory Affairs, Quality, and Operational Excellence at Syros Pharmaceuticals.

Jason Keyes: Chief Financial Officer and Executive Vice President. Appointed in May 2025, Mr. Keyes brings extensive financial leadership experience to the company.

Leadership Changes

Recent significant appointments include Dr. Geoff Oxnard as Chief Medical Officer and Executive Vice President in January 2025, Dr. Ashley Preston as Senior Vice President and Head of Regulatory Affairs and Quality Assurance in January 2025, and Jason Keyes as Chief Financial Officer and Executive Vice President in May 2025.

Competitor Profile

Market Insights and Dynamics

The global oncology market was valued at approximately $198.5 billion in 2020 and is projected to reach $246.9 billion by 2024, growing at a CAGR of 5.9%. Similarly, the autoimmune disease market is estimated to reach approximately $139.0 billion by 2027. This growth is driven by increasing prevalence rates, advancements in targeted therapies, and rising healthcare expenditures.

Competitor Analysis

BlossomHill Therapeutics operates in a competitive landscape alongside major pharmaceutical companies such as Pfizer, Roche, and Merck, which have significant resources and established market presence. Biotechnology firms like Amgen, Gilead Sciences, and Biogen also focus on developing targeted therapies in oncology and autoimmune disorders. Emerging startups and biosimilar manufacturers further intensify competition by introducing novel approaches and more affordable alternatives.

Strategic Collaborations and Partnerships

BlossomHill Therapeutics has established strategic partnerships with leading research institutions, including Johns Hopkins University and MD Anderson Cancer Center. These collaborations enhance the company's research capabilities, provide access to cutting-edge clinical trials, and strengthen the credibility of its therapeutic candidates.

Operational Insights

In the biopharmaceutical industry, the bargaining power of suppliers is significant due to the limited number of specialized raw material providers and high switching costs. Customers, including healthcare providers and patients, have increasing influence due to the availability of alternative therapies and heightened expectations. The industry is characterized by intense competitive rivalry, necessitating continuous innovation and substantial R&D investment. High barriers to entry, including substantial R&D costs and regulatory hurdles, deter new entrants but also protect established companies like BlossomHill Therapeutics.

Strategic Opportunities and Future Directions

BlossomHill Therapeutics is poised to capitalize on the growing demand for targeted therapies in oncology and autoimmune disorders. Advancements in technology and research methods present opportunities to improve drug development efficiency. Strategic partnerships with larger pharmaceutical firms could enhance market reach and resource sharing. Increasing investment in the biopharmaceutical sector provides avenues for additional funding. Expansion into emerging markets with rising healthcare needs offers potential for growth. Leveraging digital health technologies can improve patient engagement and monitoring, aligning with the company's commitment to precision medicine.